Tamer AKSOY, Esra ARSLAN, Cihan GÜNDOGAN, Göksel ALÇIN

ELASTOFIBROMA DORSIDE GA-68 DOATATE PET-BT ILE GÖSTERILEN SOMATOSTATIN RESEPTÖR EKSPRESYONU

Elastofibroma dorsi sıklıkla yaşlı popülasyonda gözlenen, yavaş büyüyen bir infraskapuler bölge yerleşimli konnektif doku tümörüdür. Sıklıkla BT, MR, USG ve PET gibi çeşitli yöntemler ile saptanırlar. Somatostatin inhibitör ve nörotransmitter özellikleri ile bilinen endojen bir hormondur. Radyoaktif işaretli bir somatostatin analoğu olan Ga-68 DOTATATE pek çok doku ve tümörde değişen oranlarda tutum gösterebilir. Bu olgu sunumunda, elastofibroma dorsinin reseptör ekspresyonları anlatılmakta ve ED ile uyumlu yumuşak doku lezyonlarında Ga-68 DOTATE PET-BT ile gösterilen somatostatin reseptör ekspresyonu anlatılmaktadır. Bilgimize göre bu olgu sunumu, elastofibroma dorsideki somatostatin ekspresyonun gösterildiği literatürdeki ikinci bildiridir

Somatostatin Receptors of Elastofibroma Dorsi, Shown With Ga-68 Dotatate Pet-Ct

Elastofibroma dorsi is a rare, benign, slowly-growing connective-tissue tumor that occurs most often in the infrascapular area in elderly people. It can be detected with various imaging modalities, like CT, MRI, USG and PET. Somatostatin is an endogenous hormone known by its inhibitory and neurotransmitter effects. Ga-68 DOTATATE which is a radiolabeled somatostatin analogue may show various uptake in physiological structures and also in tumor cells. Here in this case report, we describe the receptor expression of ED and present a case whose Ga-68 DOTATATE PET-CT scan revealed bilateral infrascapular soft tissue lesions, consistent with elastofibroma dorsi. According to our knowledge, this is the second case report in the literature, showing somatostatin receptor expression in elastofibroma dorsi

Keywords:

Elastofibroma dorsi, somatostatin receptor, Ga-68 DOTATATE, PET-CT,

PDF

___

Jarvi O, Saxen E. Elastofibroma dorse. Acta Pathol Microbiol Scand Suppl 1961;51:83–4. https://pubmed.ncbi.nlm.nih.gov/13789598/

Nagamine N, Nohara Y, Ito E. Elastofibroma in Okinawa. A clinicopathologic study of 170 cases. Cancer 1982;50:1794–805. [CrossRef]

Brandser EA, Goree JC, El-Khoury GY. Elastofibroma dorsi: prevalence in an elderly patient population as revealed by CT. AJR Am J Roentgenol 1998;171:977–80. [CrossRef]

Kransdorf MJ, Meis JM, Montgomery E. Elastofibroma: MR and CT appearance with radiologic-pathologic correlation. AJR Am J Roentgenol 1992;159:575–9. [CrossRef]

Järvi OH, Länsimies PH. Subclinical elastofibromas in the scapular region in an autopsy series. Acta Pathol Microbiol Scand A 1975;83:87–108. [CrossRef]

Fang N, Wang Y, Zeng L, Wu Z, Cui X, Wang Q, et al. Characteristics of elastofibroma dorsi on PET/CT imaging with (18)F-FDG. Clin Imaging 2016;40:110–3. [CrossRef]

Gorin MA, Marashdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP. Uptake of the prostate-specific membrane antigen- targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Nucl Med Commun 2017;38:795–8. [CrossRef]

Ishiyama M1, Vesselle H. 68Ga DOTATATE PET/CT Imaging of Elastofibroma Dorsi. Clin Nucl Med 2018;43:e154–5. [CrossRef]

Kayaselçuk F, Demirhan B, Kayaselçuk U, Ozerdem OR, Tuncer I. Vimentin, smooth muscle actin, desmin, S-100 protein, p53, and estrogen receptor expression in elastofibroma and nodular fasciitis. Ann Diagn Pathol 2002;6:94–9. [CrossRef]